Search Results - myelin

3 Results Sort By:
Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection
This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and...
Published: 10/28/2024   |   Inventor(s): Cynthia Tifft, Sergio Rosenzweig, David Adams, Lynne Wolfe, William Gahl
Keywords(s): Cell, Defect, GLYCOPROTEIN, Glycosidase, Human, Lines, Mannosyl, MOG, MOGS, MYELIN, Oligodendrocyte, Olygosaccharide, VLXXXX, VPXXXX, WIXXXX
Category(s): TherapeuticArea > Endocrinology, TherapeuticArea > Infectious Disease, TherapeuticArea > Dental, TherapeuticArea > Cardiology, TherapeuticArea > Ophthalmology, TherapeuticArea > Oncology, Application > Research Materials
Myelin Basic Protein-specific T cell Clones TL3A6, TL5F6, and TL5G7
Autoreactive T cell clones such as TL3A6 and TL5F6 that recognize an autoantigen, which is potentially relevant for an autoimmune disease, for example, multiple sclerosis (MS), offer the potential to examine the disease pathogenesis and develop new treatments. Such treatments aim at disrupting or interfering with the specific interaction between autoreactive...
Published: 4/8/2024   |   Inventor(s): Roland Martin, Henry McFarland
Keywords(s): ac5AXX, AC5XXX, ACXXXX, AXXXXX, BASIC, Cell, CLONES, Listed LPM Maddox as of 4/15/2015, MYELIN, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROTEIN-SPECIFIC, T, TL3A6, TL5G7.
Category(s): Collaboration Sought > Licensing
Antigen-Specific Tolerizing Treatment for Multiple Sclerosis
Localized, Antigen-Specific, Immunomodulatory Treatment for Multiple Sclerosis Without Global ImmunosuppressionThis antigen-specific microparticle therapy is a robust and highly efficacious, localized treatment for multiple sclerosis (MS) without provoking global immunosuppression. MS is the most common, potentially disabling, neurological disease typically...
Published: 7/18/2023   |   Inventor(s): Dorina Avram, Benjamin Keselowsky
Keywords(s): antigen specific, microparticle deliver, multiple sclerosis, myelin, Therapeutic, Therapy
Category(s): Technology Classifications > Human Health Care > Therapeutics